[{"id":"36e68fbc-8506-4572-acf5-3e86f4ea808b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949125","created_at":"2023-08-14T10:11:12.134Z","updated_at":"2025-02-25T15:28:11.863Z","phase":"Phase 1","brief_title":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT05949125","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-201"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-10"}]